|
| 伊格列净对2型糖尿病患者血压血脂影响的系统评价 |
| A Systematic Review of the Effect of Ipragliflozin on Blood Pressure and Blood Lipids in Patients with Type 2 Diabetes Mellitus |
| |
| DOI： |
| 中文关键词: 伊格列净 2型糖尿病 血压 血脂 系统评价 Meta分析 |
| 英文关键词:Ipragliflozin Type 2 diabetes mellitus Blood pressure Blood lipids Systematic review Meta analysis |
| 基金项目:四川省软科学研究计划项目(编号：2014ZR0088) |
|
| 摘要点击次数: 1341 |
| 全文下载次数: 646 |
| 中文摘要: |
| 摘 要 目的：系统评价伊格列净对2型糖尿病患者血压血脂的影响。方法：计算机检索PubMed、Embase、Medline、The Cochrane Library、CNKI、Wanfang Data、VIP、SinoMed数据库，纳入伊格列净治疗2型糖尿病的随机对照试验（randomized controlled trials，RCTs），检索时限均为建库至2017年8月。对纳入研究进行偏倚风险评价，并使用RevMan 5.3.5软件进行Meta分析。结果：共纳入9项RCTs，共计1 547例患者。Meta分析结果显示，伊格列净与安慰剂比较能显著降低2型糖尿病患者的收缩压[MD=-3.44，95%CI（-4.77, -2.10），P＜0.000 01]及舒张压[MD=-1.99，95%CI（-2.95,-1.04），P＜0.000 1]；且能有效降低三酰甘油[MD=-17.92，95%CI（-27.39，-8.46），P=0.000 2]，升高高密度脂蛋白胆固醇[MD=2.12，95%CI（0.72，3.53），P=0.003]，然而两组在降低总胆固醇和低密度脂蛋白胆固醇方面的差异无统计学意义（P＞0.05）。结论：与安慰剂相比，伊格列净能显著降低2型糖尿病患者的收缩压、舒张压和三酰甘油，升高高密度脂蛋白胆固醇，对患者的血压血脂都有一定的改善作用。受纳入研究数量和质量的限制，上述结论尚待更多高质量研究予以验证。 |
| 英文摘要: |
| ABSTRACT Objective:To evaluate the effect of ipragliflozin on blood pressure and blood lipids in patients with type 2 diabetes mellitus. Methods: Randomized controlled trials (RCTs) regarding type 2 diabetes mellitus treated by ipragliflozin were searched in the PubMed, Embase, Medline, The Cochrane Library, CNKI, Wanfang Data, VIP, SinoMed from inception to August 2017. Quality of each RCT was assessed, and the results were analyzed by RevMan 5.3.5 software. Results:A total of 1 547 patients in 9 RCTs were included. Meta analysis showed that, the experiment group (treated by ipragliflozin) exhibited a statistically significant decrease compared with the control group (treated by placebo) with respect to changes in systolic blood pressure [MD=-3.44, 95%CI(-4.77,-2.10), P＜0.000 01] ,diastolic blood pressure [MD=-1.99, 95%CI(-2.95, -1.04), P＜0.000 1], and triglyceride levels [MD=-17.92, 95%CI(-27.39，-8.46), P=0.000 2], yet an increase in HDL C levels [MD=2.12, 95%CI(0.72, 3.53), P=0.003]. There were no significant differences in the changes from baseline between the experiment group and control group for TC levels and LDL C levels (P＞0.05). Conclusion: Compared with placebo, ipragliflozin significantly reduces systolic blood pressure, diastolic blood pressure and triglyceride in patients with type 2 diabetes mellitus, and increases high density lipoprotein, which had a significant effect on blood pressure and blood lipids. Due to limited quantity and quality of the included studies, more high quality studies were need to verify above conclusions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
